Insulet Corp (PODD) · Nov 20, 2026 · Exec change

Insulet board adds back former Abiomed CEO after campaign

Minogue returns — Class I term runs through 2029; $121,700 prorated equity grant

Insulet’s board reappointed former Abiomed CEO Michael Minogue after his Massachusetts campaign ended, restoring medtech experience but not changing strategy.

Insulet is scaling the Omnipod automated-insulin-delivery platform, with its next growth leg aimed at underpenetrated type 2 diabetes and upcoming products including Omnipod 6 and a fully closed-loop system.

The filing restores experienced medtech oversight, but does not alter the operating story. Insulet reappointed Michael Minogue, who previously spent nearly two decades at Abiomed and had served on Insulet’s board since 2017 before stepping down for his Massachusetts gubernatorial campaign. 〔0〕 〔1〕 His return is modestly useful given Insulet’s medtech expansion agenda, but it is governance continuity rather than a new strategic decision.

The timing makes this partly known, not a surprise strategic hire. The 2026 proxy had already identified Minogue as a Class I director with a term extending to 2029, so the board seat and his underlying relationship with Insulet were established before his campaign-related resignation. The new information is the restoration of that seat after the election, not a change in management or direction.

The cost is routine and immaterial to the business trajectory. Minogue will receive a prorated restricted-stock-unit grant valued at approximately $121,700 against the normal $260,000 annual equity award.

Bottom line: This closes a temporary board vacancy and brings back a proven medical-device operator, but it leaves Insulet’s growth plan and execution priorities essentially unchanged. It's a small governance positive, not a business-changing event.

Original filing on SEC EDGAR

More Insulet Corp news

Insulet board adds back former Abiomed CEO after campaign | PODD Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.